There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Percutaneous treatment of hepatocellular carcinoma (HCC) encompasses a vast range of
techniques, including monopolar radiofrequency ablation (RFA), multibipolar RFA …